Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension
The researchers are investigating if changing an individual's behaviors may have an impact on outcomes for patients with pulmonary arterial hypertension (PAH).
- Trial name
- PaRTAkE-PH (NCT04254289)
- Testing
- Usual Care, Home-based exercise program
- Where
- United States
- Sponsor
- University of Michigan
Pulmonary Arterial Hypertension
Eisenmenger Quality Enhancement Research Initiative
Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment.
- Trial name
- ES-QuERI (NCT01623492)
- Testing
- Subjects with diagnosis of Eisenmenger Syndrome
- Volunteers
- 193 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH
Prospective, multi-center, open-label, single-arm, Phase 3b extension study of macitentan in patients with PAH. To assess the long-term safety of macitentan in patients with pulmonary arterial hypertension (PAH) beyond treatment…
- Trial name
- NCT02112487
- Testing
- Macitentan
- Where
- 32 sites in France, Italy and 1 more
- Volunteers
- 88 people
- Sponsor
- Actelion
Pulmonary Hypertension Secondary
Pulmonary Artery Pressure in COVID-19 Survivors
Post COVID-19 pulmonary hypertension can develop as a result of lung parenchymal damage and altered pulmonary circulation induced by COVID-19 infection.
- Trial name
- NCT05993338
- Testing
- right heart catheterization (RHC).
- Where
- Egypt
- Volunteers
- 15 people
- Sponsor
- Mansoura University Hospital
Pulmonary Arterial Hypertension
Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension
The objective of the study is to monitor physical activity longitudinally with a wrist activity tracker specifically in PAH patients newly initiating ERA therapy and to assess the correlation with the 6MWD at different time…
- Trial name
- LONGACT (NCT02309463)
- Testing
- Endothelin receptor antagonist therapy
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with Pulmonary Arterial Hypertension…
- Trial name
- IMPAHCT (NCT05036135)
- Testing
- AV-101
- Where
- 128 sites in United States, Argentina and 24 more
- Volunteers
- 202 people
- Sponsor
- Aerovate Therapeutics
Pulmonary Arterial Hypertension, Eisenmenger Syndrome
Respiratory and Physical Therapy in Patients With Associated Pulmonary Arterial Hypertension (APAH) With Congenital Heart Defects
The purpose of this study is to investigate the influence of physical training on exercise capacity, quality of life, functional class, oxygen consumption and right ventricular function in patients with severe associated…
- Trial name
- NCT01397110
- Testing
- respiratory and exercise therapy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Pulmonary Hypertension
Continuous Effect Of Rehabilitation Training On Pulmonary Arterial Hypertension Patients
This multicenter, open label, double-arm study aims at investigating the the continuous effect of long-Term rehabilitation training on clinical improvement(ITTCI) and cardiopulmonary function in pulmonary arterial hypertension…
- Trial name
- NCT07149935
- Testing
- Rehabilitation Training
- Where
- China
- Volunteers
- 104 people
- Sponsor
- RenJi Hospital
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Registry for Pulmonary Hypertension in China
1. To characterize the demographics and clinical course of the patient population diagnosed as having WHO group I pulmonary arterial hypertension and WHO group IV pulmonary hypertension due to chronic thromboembolic pulmonary…
- Conditions
- Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Death
- Trial name
- NCT01417338
- Where
- China
- Volunteers
- 3,079 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Pulmonary Arterial Hypertension, Diffuse Interstitial Lung Disease
Pulmonary Hypertension in Interstitial Lung Disease
HYPID study is an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided catheterization.
- Trial name
- HYPID (NCT01443598)
- Where
- France
- Volunteers
- 224 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Pulmonary Hypertension, Pulmonary Arterial Hypertension
The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension
The aim of this study is to 1) descriptively report possible in flight events and 2) to provide regression analysis if the number of events are statistically significant in their prevalence and thus are useful in finding possible…
- Trial name
- PEGASUS (NCT03051763)
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 1,000 people
- Sponsor
- University of Giessen
Obstructive Sleep Apnea
Correlation Between Serum Uric Acid and Pulmonary Hypertension in Obstructive Sleep Apnea Syndrome
This study aimed to correlate serum uric acid levels and PAH in OSAHS patients.
- Trial name
- NCT05967754
- Testing
- polysomnography
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Pulmonary Arterial Hypertension
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
Study KER-012-A201 is Phase 2, double-blind, randomized, placebo-controlled study to determine the efficacy and safety of KER-012 compared to Placebo in adults with PAH (WHO Group 1 PH) on stable background PAH therapy.
- Trial name
- NCT05975905
- Testing
- Dose A KER-012, Dose B KER-012, Dose C KER-012
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 113 people
- Sponsor
- Keros Therapeutics, Inc.
Pulmonary Arterial Hypertension
HRV as a Marker of Treatment Response in PAH Arterial Hypertension
This is a prospective longitudinal cohort study to determine the value of HRV obtained using noninvasive actigraphy to quantify the response to pulmonary vasodilator therapy in newly diagnosed PAH patients
- Trial name
- NCT04451850
- Testing
- Noninvasive actigraphy monitor
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Cincinnati
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Six-minute Walking Distance Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on six-minute walking distance and other scores in patients with pulmonary arterial…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, Six-minute Walk Test, NYHA
- Trial name
- NCT07797166
- Testing
- Re-Ascent sea level to 2850m
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
This is a multi-center, open-label study for eligible participants who were actively participating in the BPS-314d-MR-PAH-302 double-blind study (NCT01908699) at the time the study was concluded.
- Trial name
- BEAT OLE (NCT03657095)
- Testing
- Esuberaprost
- Where
- 45 sites in United States, Israel
- Volunteers
- 112 people
- Sponsor
- Lung Biotechnology PBC
Pulmonary Arterial Hypertension
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension
The rationale for this study is that GLP-1 agonist treatment is likely to influence myocardial substrate utilisation, changing the predominant source of metabolic energy within the heart to a more energetically efficient form.
- Trial name
- NCT07737522
- Testing
- GLP-1 agonist
- Volunteers
- 32 people
- Sponsor
- Imperial College London
Coronary Artery Disease, Heart Failure
Stress Echo 2020 - The International Stress Echo Study
Background: Stress echocardiography (SE) has an established role in evidence-based guidelines, but recently the breadth and variety of applications has extended well beyond coronary artery disease (CAD).
- Conditions
- Coronary Artery Disease, Heart Failure, Hypertrophic Cardiomyopathy, Aortic Valve Disease
- Trial name
- SE2020 (NCT03049995)
- Testing
- Left ventricular contractile reserve SE, B-lines SE, Left ventricular outflow tract gradient SE
- Where
- Italy
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Fatebenefratelli Hospital
Pulmonary Hypertension
Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).
This study is a prospective, randomized, double-blind, study of H01 (Hymecromone) in adults with pulmonary hypertension (PH). The primary objective of this study is to evaluate the safety and tolerability of oral H01 and the…
- Trial name
- SATURN (NCT05128929)
- Testing
- Hymecromone (H01)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Pulmonary Artery Hypertension, Chronic Hepatitis c
Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection
The purpose of this study is the evaluation of PAH in patients, who are treated with DAA medication for HCV infection.
- Trial name
- NCT04094272
- Testing
- transthoracic doppler-echocardiography (TTE)
- Where
- Switzerland
- Volunteers
- 49 people
- Sponsor
- Kantonsspital Olten